FDA accepts new drug application, prioritizes review for potential Stargardt treatment

The U.S. Food and Drug Administration has accepted Belite Bio’s new drug application for tinlarebant, an oral drug to treat Stargardt disease. The FDA also designated the treatment as priority review, accelerating the deadline for a marketing decision to February 12, 2027. If approved for marketing, tinlarebant stands to become the first approved treatment for Stargardt disease, a genetic eye disorder often diagnosed in childhood that causes central vision loss.

Tinlarebant continues to hit milestones as the first potential Stargardt treatment to make it this far in the FDA approval process. Belite Bio filed the new drug application (NDA) for tinlarebant with the FDA in June 2026. New drug applications that are accepted are typically reviewed in 10 months unless prioritized to have an expedited six-month review, as tinlarebant was, under the Prescription Drug User Fee Act (PDUFA).

“To date, a Stargardt diagnosis has meant patients face progressive vision loss,” said Dr. Amy Laster, chief scientific officer at Foundation Fighting Blindness. “The potential for approval of a first-ever treatment for Stargardt disease changes the narrative from managing the condition, to a treatment option. This is inspirational for all members of our community.”

Stargardt is typically caused by two mutations in the ABCA4 gene, which cause toxic byproducts from the processing of vitamin A to build up and damage the retina, creating areas where retinal cells are lost, called lesions, that cause vision loss. Tinlarebant is a once-daily oral pill that lowers levels of a protein that carries vitamin A from the liver to the eye, thus reducing build-up of vitamin A-based toxins in the eye.

Belite Bio previously shared successful results from the drug’s phase 3 clinical trial in December 2025. In that trial, tinlarebant slowed down the growth of lesion area by 36 percent, compared to patients who received a placebo. Tinlarebant had a strong safety profile in this clinical trial. Common adverse effects reported included headaches, xanthopsia (yellow vision), delayed dark adaptation, and impairment of night vision. The majority of vision-related side effects were mild, and most resolved during the trial.

“Belite Bio's clinical development program for tinlarebant is guided by rigorous science and a deep commitment to the Stargardt community. We are profoundly grateful to everyone who has participated in our clinical trials, and to the broader community who helped make this research possible,” said Amy Fisher, Vice President and Head of Patient Advocacy at Belite Bio. “The FDA's acceptance of our New Drug Application (NDA) is an important step forward. As we move through the regulatory process and look ahead, the experiences and needs of people living with Stargardt disease will remain at the center of our work.”

Belite Bio is also currently conducting additional clinical trials for tinlarebant in Stargardt patients in the U.S., U.K., and Japan. Because of underlying similarities between Stargardt disease and some other forms of macular degeneration, the treatment could also be used to treat patients with an advanced form of dry age-related macular degeneration called geographic atrophy. A phase 3 clinical trial evaluating tinlarebant for treating geographic atrophy is ongoing.

ProgStar, the Foundation’s natural history study of patients with Stargardt disease, played a role in informing Belite Bio’s clinical trial design. ProgStar followed 259 patients for two years, collecting imaging and medical record data to help clinicians and researchers understand how the disease progresses.

Tinlarebant is one of several potential treatments being developed for patients with an ABCA4-associated Stargardt diagnosis. See the Foundation’s Clinical Trial Pipeline for the latest on treatments making their way through clinical trials.